SV2A protein is a broad-spectrum anticonvulsant target: Functional correlation between protein binding and seizure protection in models of both partial and generalized epilepsy

Neuropharmacology

Volumn 54, Issue 4, 2008, Pages 715-720

  Kaminski, Rafal M ^a   Matagne, Alain ^a   Leclercq, Karine ^a   Gillard, Michel ^a   Michel, Philippe ^a   Kenda, Benoit ^a   Talaga, Patrice ^a   Klitgaard, Henrik ^a  

^a UCB PHARMA   (Belgium)

Author keywords

Antiepileptic drugs; Epilepsy; Mouse; Rat; SV2A; Synaptic vesicle

Indexed keywords

BINDING PROTEIN; CALCIUM CHANNEL; CARBAMAZEPINE; CLONAZEPAM; ETHOSUXIMIDE; ETIRACETAM; FELBAMATE; GABAPENTIN; LAMOTRIGINE; MEMBRANE PROTEIN; PHENOBARBITAL; PHENYTOIN; PROTEIN SV2A; SODIUM CHANNEL; TIAGABINE; TOPIRAMATE; UNCLASSIFIED DRUG; VALPROIC ACID; VIGABATRIN; ZONISAMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG STRUCTURE; DRUG TARGETING; EPILEPSY; FEMALE; GENERALIZED EPILEPSY; MALE; MOUSE; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; RAT; SEIZURE; SYNAPSE VESICLE; TEMPORAL LOBE EPILEPSY;

ACOUSTIC STIMULATION; ANIMALS; ANTICONVULSANTS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; EPILEPSIES, PARTIAL; EPILEPSY, GENERALIZED; FEMALE; INHIBITORY CONCENTRATION 50; LIGANDS; MALE; MEMBRANE GLYCOPROTEINS; MICE; NERVE TISSUE PROTEINS; PROTEIN BINDING;

EID: 38749128706     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2007.11.021     Document Type: Article

References (38)

1. Badiu C.I. Sensitivity of thalamic GABAergic currents to clonazepam does not differ between control and genetic absence epilepsy rats. Brain Res. 1026 (2004) 261-266
2. Ben Menachem E., and Falter U. Efficacy and tolerability of levetiracetam 3000 mg/d in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. European Levetiracetam Study Group. Epilepsia 41 (2000) 1276-1283
3. Berkovic S.F., Knowlton R.C., Leroy R.F., Schiemann J., and Falter U. Placebo-controlled study of levetiracetam in idiopathic generalized epilepsy. Neurology 69 (2007) 1751-1760
4. Bouwman B.M., and van Rijn C.M. Effects of levetiracetam on spike and wave discharges in WAG/Rij rats. Seizure 13 (2004) 591-594
5. Coenen A.M., Blezer E.H., and van Luijtelaar E.L. Effects of the GABA-uptake inhibitor tiagabine on electroencephalogram, spike-wave discharges and behaviour of rats. Epilepsy Res. 21 (1995) 89-94
6. Crowder K.M., Gunther J.M., Jones T.A., Hale B.D., Zhang H.Z., Peterson M.R., Scheller R.H., Chavkin C., and Bajjalieh S.M. Abnormal neurotransmission in mice lacking synaptic vesicle protein 2A (SV2A). Proc. Natl. Acad. Sci. U.S.A. 96 (1999) 15268-15273
7. Custer K.L., Austin N.S., Sullivan J.M., and Bajjalieh S.M. Synaptic vesicle protein 2 enhances release probability at quiescent synapses. J. Neurosci. 26 (2006) 1303-1313
8. De Sarro G., Spagnolo C., Gareri P., Gallelli L., and De Sarro A. Gabapentin potentiates the antiseizure activity of certain anticonvulsants in DBA/2 mice. Eur. J. Pharmacol. 349 (1998) 179-185
9. Frey H.H., and Bartels I. Felbamate and meprobamate: a comparison of their anticonvulsant properties. Epilepsy Res. 27 (1997) 151-164
10. Gillard M., Fuks B., Michel P., Vertongen P., Massingham R., and Chatelain P. Binding characteristics of [3H]ucb 30889 to levetiracetam binding sites in rat brain. Eur. J. Pharmacol. 478 (2003) 1-9
11. Gower A.J., Hirsch E., Boehrer A., Noyer M., and Marescaux C. Effects of levetiracetam, a novel antiepileptic drug, on convulsant activity in two genetic rat models of epilepsy. Epilepsy Res. 22 (1995) 207-213
12. Gurbanova A.A., Aker R., Berkman K., Onat F.Y., van Rijn C.M., and van Luijtelaar G. Effect of systemic and intracortical administration of phenytoin in two genetic models of absence epilepsy. Br. J. Pharmacol. 148 (2006) 1076-1082
13. Janz R., Goda Y., Geppert M., Missler M., and Sudhof T.C. SV2A and SV2B function as redundant Ca2+ regulators in neurotransmitter release. Neuron 24 (1999) 1003-1016
14. Klitgaard H. Levetiracetam: the preclinical profile of a new class of antiepileptic drugs?. Epilepsia 42 Suppl. 4 (2001) 13-18
15. Klitgaard H. Antiepileptic drug discovery: lessons from the past and future challenges. Acta Neurol. Scand. Suppl. 181 (2005) 68-72
16. Klitgaard H., Matagne A., Gobert J., and Wülfert E. Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy. Eur. J. Pharmacol. 353 (1998) 191-206
17. Leclercq K., Dassesse D., Lambeng N., Klitgaard H., and Matagne A. Unaltered seizure susceptibility contrasts accelerated kindling acquisition in heterozygous SV2A KO mice. Neuroscience Meeting Planner (2006), Society for Neuroscience, Atlanta, GA Online. 82.7/LL38
18. Liu L., Zheng T., Morris M.J., Wallengren C., Clarke A.L., Reid C.A., Petrou S., and O'Brien T.J. The mechanism of carbamazepine aggravation of absence seizures. J. Pharmacol. Exp. Ther. 319 (2006) 790-798
19. Lynch B.A., Lambeng N., Nocka K., Kensel-Hammes P., Bajjalieh S.M., Matagne A., and Fuks B. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc. Natl. Acad. Sci. U.S.A. 101 (2004) 9861-9866
20. Matagne A., and Klitgaard H. Validation of corneally kindled mice: a sensitive screening model for partial epilepsy in man. Epilepsy Res. 31 (1998) 59-71
21. Molinoff P.B., Wolfe B.B., and Weiland G.A. Quantitative analysis of drug-receptor interactions: II. Determination of the properties of receptor subtypes. Life Sci. 29 (1981) 427-443
22. Nakamura J., Tamura S., Kanda T., Ishii A., Ishihara K., Serikawa T., Yamada J., and Sasa M. Inhibition by topiramate of seizures in spontaneously epileptic rats and DBA/2 mice. Eur. J. Pharmacol. 254 (1994) 83-89
23. Noachtar, S., Andermann, E., Meyvisch, P., Andermann, F., Gough, W.B., Schiemann-Delgado, J., in press. The N166 Levetiracetam Study Group. Levetiracetam for the treatment of idiopathic generalized epilepsy with myoclonic seizures. Neurology.
24. Noyer M., Gillard M., Matagne A., Henichart J.P., and Wülfert E. The novel antiepileptic drug levetiracetam (ucb L059) appears to act via a specific binding site in CNS membranes. Eur. J. Pharmacol. 286 (1995) 137-146
25. Potschka H., and Löscher W. Corneal kindling in mice: behavioral and pharmacological differences to conventional kindling. Epilepsy Res. 37 (1999) 109-120
26. Racine R.J. Modification of seizure activity by electrical stimulation. II. Motor seizure. Electroencephalogr. Clin. Neurophysiol. 32 (1972) 281-294
27. Rigoulot M.A., Boehrer A., and Nehlig A. Effects of topiramate in two models of genetically determined generalized epilepsy, the GAERS and the Audiogenic Wistar AS. Epilepsia 44 (2003) 14-19
28. Rogawski M.A., and Löscher W. The neurobiology of antiepileptic drugs. Nat. Rev. Neurosci. 5 (2004) 553-564
29. Shorvon S.D., Lowenthal A., Janz D., Bielen E., and Loiseau P. Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. European Levetiracetam Study Group. Epilepsia 41 (2000) 1179-1186
30. Suzdak P.D., Frederiksen K., Andersen K.E., Sorensen P.O., Knutsen L.J., and Nielsen E.B. NNC-711, a novel potent and selective gamma-aminobutyric acid uptake inhibitor: pharmacological characterization. Eur. J. Pharmacol. 224 (1992) 189-198
31. van Luijtelaar E.L. Spike-wave discharges and sleep spindles in rats. Acta Neurobiol. Exp. (Wars) 57 (1997) 113-121
32. van Rijn C.M., Weyn Banningh E.W., and Coenen A.M. Effects of lamotrigine on absence seizures in rats. Pol. J. Pharmacol. 46 (1994) 467-470
33. van Rijn C.M., Sun M.S., Deckers C.L., Edelbroek P.M., Keyser A., Renier W., and Meinardi H. Effects of the combination of valproate and ethosuximide on spike wave discharges in WAG/Rij rats. Epilepsy Res. 59 (2004) 181-189
34. Vartanian M.G., Radulovic L.L., Kinsora J.J., Serpa K.A., Vergnes M., Bertram E., and Taylor C.P. Activity profile of pregabalin in rodent models of epilepsy and ataxia. Epilepsy Res. 68 (2006) 189-205
35. Vergnes M., Marescaux C., Micheletti G., Depaulis A., Rumbach L., and Warter J.M. Enhancement of spike and wave discharges by GABAmimetic drugs in rats with spontaneous petit-mal-like epilepsy. Neurosci. Lett. 44 (1984) 91-94
36. White H.S., Wolf H.H., Swinyard E.A., Skeen G.A., and Sofia R.D. A neuropharmacological evaluation of felbamate as a novel anticonvulsant. Epilepsia 33 (1992) 564-572
37. Xu T., and Bajjalieh S.M. SV2 modulates the size of the readily releasable pool of secretory vesicles. Nat. Cell Biol. 3 (2001) 691-698
38. Zar J.H. Biostatistical Analysis. second ed. (1984), Prentice-Hall, Englewood Cliffs, NJ